Partnerships for Solid Targetry
The Austin Health/Ludwig Institute for Cancer Research in Victoria, Sir Charles Gairdner Hospital in Western Australia and ANSTO have developed a collaborative arrangement to provide Australian researchers access to locally produced Positron Emission Tomography (PET) isotopes.
The collaboration aims at providing radio-isotopes specifically produced by 18MeV cyclotrons equipped with solid targetry for medical research and clinical applications to the benefit of Australians. Initially Copper-64 (Cu-64); Zirconium-89 (Zr-89) and Iodine-124 (I-124) will be produced, with Yttrium-86 (Y-86) to follow.
Access to these isotopes is through a collaborative projects management tool which will ensure availability for research is on a scientific, merit selection basis, through a fair and transparent process.
Choosing the right form
If you have limited knowledge of the field of radio-pharmaceuticals application we suggest you begin with an EOI. EOIs are considered by the Scientific Review Committee (SRC) who will appoint a researcher (Champion) to help you in drafting a detailed project proposal. The researcher can be a member from any of the collaborating institutions.
The SRC, which is composed of 2 members from each collaborating institution plus one independent advisor, will review the portfolio of project proposals and will select the projects to be supplied with radio-isotopes based on the following evaluation criteria:
i. Scientific merit
ii. Impact area, expected outcomes and benefits for the community
iii. Resources allocation
The SRC may request the input of experts to assess any particular aspect of a project proposal.
Project management process
On approval of the project, the SRC will require the nomination a project coordinator by the project CI. The project coordinator is responsible for the deliverables and timelines agreed to with the SRC, providing quarterly progress reports, and providing a project close out report which include outputs and outcomes from the project.